Loading...
Cipla Limited — Bleomycin Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #7 for Bleomycin · $250.0K export value · DGFT Verified
Cipla Limited is the #7 Indian exporter of Bleomycin with $250.0K in export value and 5 verified shipments. Cipla Limited holds a 4.5% market share in Bleomycin exports across 2 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| SOUTH AFRICA | $400.0K | 8 | 11.0% |
| MOZAMBIQUE | $400.0K | 8 | 11.0% |
| UZBEKISTAN | $351.9K | 11 | 9.7% |
| MEXICO | $346.6K | 36 | 9.6% |
| COLOMBIA | $345.7K | 20 | 9.5% |
| HUNGARY | $336.2K | 8 | 9.3% |
| EGYPT | $310.8K | 15 | 8.6% |
| UKRAINE | $237.0K | 11 | 6.5% |
| SAUDI ARABIA | $189.1K | 64 | 5.2% |
| UNITED STATES | $160.2K | 45 | 4.4% |
India exports Bleomycin to 119 countries. The top destination is SOUTH AFRICA (11.0%), followed by MOZAMBIQUE and UZBEKISTAN.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CENTRAL DE MEDICAMENTOS E ARTIGOS. | MOZAMBIQUE | $300.0K | 6 |
| CPC "BIOCON" LLC | UKRAINE | $235.7K | 7 |
| BIOSISTEMAS Y SEGURIDAD PRIVADA SA | MEXICO | $200.0K | 4 |
| NATIONAL BANK OF EGYPT | EGYPT | $199.5K | 4 |
| ALPHARMA S.A.S. | COLOMBIA | $150.7K | 12 |
| VEF SAU | UZBEKISTAN | $150.0K | 3 |
India exported $3.6M worth of Bleomycin through 1,101 shipments from 206 suppliers to 119 countries, serving 426 buyers globally. Cipla Limited contributes $250.0K to this total, accounting for 4.5% of India's Bleomycin exports.
Cipla Limited's average Bleomycin shipment value is $50.0K per consignment, based on 5 shipments totaling $250.0K.
Cipla Limited ranks #7 among 206 Indian Bleomycin exporters with a 4.5% market share. The top 3 exporters are VENUS REMEDIES LIMITED ($1.2M), NAPROD LIFE SCIENCES PRIVATE LIMITED ($485.6K), INFUGEN PHARMA PRIVATE LIMITED ($300.0K). Cipla Limited processed 5 shipments to 2 destination countries.
What Cipla Limited must comply with to export Bleomycin to its top destination countries
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | NV REMEDIES PRIVATE LIMITED | $290.8K | 12 | 3 | $24.2K |
| 6 | SEATRACK INTERNATIONAL TRADEX PRIVATE LIMITED | $273.1K | 6 | 2 | $45.5K |
| 7 | CIPLA LIMITED ★ | $250.0K | 5 | 2 | $50.0K |
| 5 | VIVALIA REMEDIES PRIVATE LIMITED | $200.0K | 4 | 1 | $50.0K |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 288 | 26.2% |
| SAHAR AIR CARGO ACC (INBOM4) | 248 | 22.5% |
| DELHI AIR CARGO ACC (INDEL4) | 171 | 15.5% |
| DELHI AIR | 124 | 11.3% |
| Bombay Air | 70 | 6.4% |
| Delhi Air | 29 | 2.6% |
| Bombay Air Cargo | 24 | 2.2% |
| Delhi Air Cargo | 14 | 1.3% |
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Bleomycin, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Bleomycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Bleomycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $150.0K | 3 |
| E P H K | HUNGARY | $100.0K | 2 |
| A S A S | COLOMBIA | $96.5K | 5 |
| GENERAL FOREIGN TRADE ORGANIZATION | SYRIA | $84.6K | 6 |
India's Bleomycin is purchased by 426 buyers worldwide. The top buyer is CENTRAL DE MEDICAMENTOS E ARTIGOS. (MOZAMBIQUE), followed by CPC "BIOCON" LLC and BIOSISTEMAS Y SEGURIDAD PRIVADA SA.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 8 | KHANDELWAL LABORATORIES PRIVATE LIMITED | $158.4K | 17 | 5 | $9.3K |
Cipla Limited ranks #7 among 206 Indian Bleomycin exporters. Average shipment value of $50.0K compared to the market average of $17.6K. The closest competitors by value are NV REMEDIES PRIVATE LIMITED and SEATRACK INTERNATIONAL TRADEX PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 119+ countries, 426+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Bleomycin. For current shipment-level data, contact TransData Nexus.